ClinicalTrials.gg
RecruitingNCT06024304Updated Apr 7, 2026

InterTAN: Integrated Dual Screw Design Improve Biomechanics/Function Following Fixation Surgery

An interventional study of Synthes TFNA and Trigen InterTAN in Fracture of Hip, sponsored by Paul E. Matuszewski. Recruiting at 1 site in United States. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-04-07.

Sponsored by Paul E. Matuszewski · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
55 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 133 studies in Hip Fractures with a site in United States — 22 open to participants now, 31 under way, none of them phase 3. Hip Fractures · United States.

Planned enrollment
73rd of 105
30 · median 64
Started
2025
with 4 others
No phase
62 of 133
13 open now
Primary completion
2027-01
later than 6 of 30 live
Registered
107th of 133
by date

Among the 133 studies in Hip Fractures with a site in United States, this one is the 73rd largest by planned enrollment of the 105 interventional ones that give a count, is one of 5 that started in 2025, is one of 62 with no phase, reaches primary completion later than 6 of the 30 other live ones, and was the 107th registered.

Hip Fractures

843 studies on the registry are indexed under Hip Fractures; 166 are open to participants now.

Browse Hip Fractures studies →

Open to participants now

22 of the 133 studies in Hip Fractures with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 104 Hip Fractures studies recruiting now, 82 (79%) set no upper age limit and 6 (6%) stop at 75 or younger; 12 take children under 18; 9 take healthy volunteers.

This study: 55 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 133 studies in Hip Fractures with a site in United States, or all of them as a file.
02

Study summary

The goal of this pilot, patient blinded randomized trial is to develop a mechanistic understanding of gait following fixation of unstable intertrochanteric hip fractures and return to function and pain control. The guiding hypothesis that will be tested in a subsequent clinical trial is that the InterTAN when compared to standard lag-screw cephalomedullary nails will have decreased post operative pain, earlier return to symmetric weight bearing, and quicker return to pre-injury functioning levels.

Read the detailed description

Aim 1: Determine the feasibility of conducting a randomized trial assessing gait mechanics as well as outcomes following unstable intertrochanteric femur fractures treated with cephalomedullary nails. This will be achieved by performing a pilot randomized trial comparing the InterTAN versus a single-screw design cephalomedullary nail (SSCMN). Deliverable: Preliminary data to support a larger randomized trial powered on either mechanical assessments or patient reported outcomes. Feasibility of conducting comprehensive biomechanical and patient related outcome measurements in the geriatric hip fracture population.

Aim 2: Determine the pathway to return to function and symmetric weight bearing. Load bearing will be assessed through insole monitoring during their inpatient stay and 2-weeks post-op. Additionally, analysis will be performed to measure gait for hip motion, loading, strength and functional assessments at 6,12, and 26 weeks post-op. Patients will also be assessed at 1-year for reported function as well. Hypothesis: Patients in the InterTAN group will have faster return to symmetrical weight bearing/motion and earlier return to function. Deliverable: Longitudinal data assessing return to function and weight bearing in intertrochanteric femur fractures.

Aim 3: Determine if use of the InterTAN device when compared to SSCMN results in decreased pain following unstable intertrochanteric femur fractures. Patients will be enrolled in a prospective trial with standardized pain control regimen, assessing patients for pain during their hospital stay using Area Under the Curve Analysis of Visual Analogue Pain Scores at 24, 48 and 72 hours. Similarly, opioid usage in morphine milligram equivalents will be assessed. Pain will be assessed at follow-up visits 6, 12, 26, 52 weeks. Hypothesis: The InterTAN will result in decreased pain in the immediate post-operative period and in sub-acute post-operative period.

Aim 4: Determine if the use of the InterTAN device when compared to SSCMN results in decreased healthcare utilization. Participation with therapy, hospital length of stay, discharge disposition, and time-spent in rehabilitation facility will be assessed. Hypothesis: Patients in the InterTAN group will be more likely to be discharged home, participate with therapy more, have decreased length of stay in both inpatient and outpatient units. Deliverable: Data to inform the power analysis for a larger prospective clinical trial.

03

Conditions studied

  • Fracture of Hip

Browse trials for

Keywords

  • Surgical Fixation
  • Cephalomedullary nail
04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Non-pathologic fractures
  • OTA/AO classification 31A2, 31A3 fractures
  • Ability to participate in 4-MET equivalent activities without ambulatory assistance prior to injury

Exclusion criteria

Exclusion Criteria:

  • Inability to consent
  • Inability to participate in follow-up activities
  • History of chronic pain / current opioid treatment
  • Pre-injury ambulatory status requiring assistance device
  • Neurological condition altering gait or sensation (e.g. History of stroke with altered gait, peripheral neuropathy).
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
30 participants (estimated)

Study arms

  • Active comparator
    Trigen InterTan

    Patients in this arm will be implanted with the cephalomedullary nail Trigen InterTan manufactured by Smith \& Nephew.

    Device: Trigen InterTAN

  • Active comparator
    Synthes TFNA

    Patients in this arm will be implanted with the single-screw device TFNA manufactured by DePuy Synthes.

    Device: Synthes TFNA

Interventions

  • DeviceSynthes TFNA

    Surgical fixation with single-screw device Synthes TFNA; Pelvic fractures will be repaired utilizing single-screw device Synthes TFNA.

  • DeviceTrigen InterTAN

    Surgical fixation with Smith and Nephew Trigen InterTAN cephalomedullary long nail; Pelvic fractures will be repaired utilizing Smith and Nephew Trigen InterTAN.

06

What researchers measure

Primary outcomes

  1. Change in self-reported physical function

    Patient Reported Outcomes Measurement Information System (PROMIS) Physical Function Questionnaire is a 53 question survey with a five point Likert scale ranging from 1 to 5 where a higher number indicates less physical function.

    Time frame: 2 weeks, 6 weeks, 12 weeks, 26 weeks, 12 months

  2. Change in self-reported pain

    Patient Reported Outcomes Measurement Information System (PROMIS) Pain Interference Questionnaire is a 56 question survey with a five point Likert scale ranging from 1 to 5 where a higher number indicates increased interference due to pain.

    Time frame: 2 weeks, 6 weeks, 12 weeks, 26 weeks, 12 months

Secondary outcomes

  1. Change in Functional Independence Measure

    The Functional Independence Measure (FIM) is a tool used to measure the level of disability as well as the change in patient status. FI is comprised of 18 items, grouped into 2 subscales - motor and cognition. Each item is scored on a 7 point ordinal scale, ranging from a score of 1 to a score of 7. The higher the score, the more independent the patient is in performing the task associated with that item.

    Time frame: 2 weeks, 6 weeks, 12 weeks, 26 weeks, 12 months

  2. Change in pain assessment

    Brief Pain Inventory (BPI) will be used to measure pain intensity. This is a four-item scale that measures current, worst, least, and average pain. Each of these four items are measured on a numeric scale from 0 to 10 with 0 being ''no pain'' and 10 being ''severe pain.''

    Time frame: 2 weeks, 6 weeks, 12 weeks, 26 weeks, 12 months

  3. Change in weight bearing

    The ground reaction forces of the injured and non injured limb will be evaluated over the course of recovery to assess when loading between limbs becomes symmetric during their physical therapy.

    Time frame: 2 weeks, 6 weeks, 12 weeks, 26 weeks, 12 months

  4. Change in Visual Analog Pain Score

    The visual analog pain score is a horizontal line with a scale ranging from 0 to 10 where a higher number indicates more pain.

    Time frame: 2 weeks, 6 weeks, 12 weeks, 26 weeks, 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Jan 2027, 20 months after the start.

Of 221 non-industry interventional studies with no phase under Hip Fractures, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 55. This study's planned 20 months is below that.

Counting every sponsor, half of 237 studies reached it within 29 months; a quarter within 10 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2022
First posted
Sep 6, 2023
StartActual
Apr 18, 2025
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jan 1, 2027
Last update
Apr 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06024304
Lead sponsor
Paul E. Matuszewski
Responsible party
Paul E. Matuszewski (Associate Professor, University of Kentucky) — Sponsor-investigator
First posted
Sep 6, 2023
Start date
Apr 18, 2025
Primary completion
Jan 1, 2027 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
Apr 7, 2026

Study contacts

Paul E Matuszewski, MD
Contact
pmatuszewski@uky.edu
(859) 323-5533
Matthew Eubank
Contact
mseuba01@uky.edu
(859) 323-5533
Paul Matuszewski, MD
principal investigator · University of Kentucky

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion